Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 1.00 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 1.00 |
| ▸ | LDHB | P07195 | 3/20 | 0.42 |
| ▸ | TERF2IP | Q9NYB0 | 3/20 | 0.42 |
| ▸ | SSTR5 | P35346 | 5/20 | 0.40 |
| ▸ | SSTR2 | P30874 | 3/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | TERF2 | Q15554 | 2/20 | 0.40 |
| ▸ | F11 | P03951 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Polymyxin B2 SCHEMBL15887064 | 1.00 | KDM1A (1.00) | KDM1ARCOR1LDHBTERF2IPSSTR5 | |
| SCHEMBL21504123 | 0.98 | KDM1A (0.95) | KDM1ARCOR1LDHBTERF2IPSSTR5 | |
| SCHEMBL21504375 | 0.98 | KDM1A (0.95) | KDM1ARCOR1LDHBTERF2IPSSTR5 | |
| Polymyxin B2 SCHEMBL29514784 | 0.97 | KDM1A (0.98) | KDM1ARCOR1LDHBTERF2IPSSTR5 | |
| Polymyxin B2 SCHEMBL29356304 | 0.97 | KDM1A (0.98) | KDM1ARCOR1LDHBTERF2IPSSTR5 | |
| SCHEMBL23626629 | 0.95 | KDM1A (1.00) | KDM1ARCOR1LDHBTERF2IPSSTR5 | |
| SCHEMBL21991628 | 0.95 | KDM1A (1.00) | KDM1ARCOR1LDHBTERF2IPSSTR5 | |
| SCHEMBL136097 | 0.95 | KDM1A (1.00) | KDM1ARCOR1LDHBTERF2IPSSTR5 | |
| SCHEMBL7799155 | 0.95 | KDM1A (1.00) | KDM1ARCOR1LDHBTERF2IPSSTR5 | |
| SCHEMBL16549195 | 0.95 | KDM1A (1.00) | KDM1ARCOR1LDHBTERF2IPSSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 395 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250241979-A1 | NOVEL COMPOUNDS AND THERAPEUTICS USES THEREOF | Centauri Therapeutics Limited (GB/GB) (GB) | 2025-07-31 | — | — | US | claimed |
| CN-119291073-B | Method for simultaneously detecting content of polymyxin and caspofungin and application of internal standard | 兰州大学第二医院 | 2025-05-13 | — | — | CN | claimed |
| CN-119667047-A | Analysis method of polymyxin B sulfate related substances for injection | 海南广升誉制药有限公司 | 2025-03-21 | — | — | CN | claimed |
| CN-119291073-A | Method for simultaneously detecting content of polymyxin and caspofungin, internal standard and application thereof | 兰州大学第二医院 | 2025-01-10 | — | — | CN | claimed |
| CN-117783372-B | LC-MS/MS based method for simultaneously determining amikacin and polymyxin B in blood plasma and blood serum | 裕菁科技(上海)有限公司 | 2024-07-02 | — | — | CN | claimed |
| CN-118090979-A | Method for measuring blood concentration of polymyxin E sodium mesylate and colistin in human plasma based on LC-MS/MS | 华中科技大学同济医学院附属同济医院 | 2024-05-28 | — | — | CN | claimed |
| CN-118028155-A | Novel probiotics, fermented coconut water metaplasia and application thereof in poultry feed additive | 海南大学 | 2024-05-14 | — | — | CN | claimed |
| EP-3218013-B1 | MOLECULAR PROBES FOR DETECTING GRAM-NEGATIVE BACTERIA IN VITRO AND IN VIVO | UNIV COURT UNIV OF EDINBURGH (GB) | 2024-04-17 | — | — | EP | claimed |
| CN-117783372-A | LC-MS/MS based method for simultaneously determining amikacin and polymyxin B in blood plasma and blood serum | 裕菁科技(上海)有限公司 | 2024-03-29 | — | — | CN | claimed |
| CN-116083509-A | Feeding method for improving content of polymyxin B2 in polymyxin B fermentation product | 丽珠集团福州福兴医药有限公司 | 2023-05-09 | — | — | CN | claimed |
| EP-1558748-A2 | CELL LYSIS COMPOSITIONS, METHODS OF USE, APPARATUS, AND KIT | PROMEGA CORPORATION (US) | 2005-08-03 | — | — | EP | claimed |
| US-20040101947-A1 | Cell lysis composition, methods of use, apparatus and kit | PROMEGA CORPORATION | 2004-05-27 | — | — | US | claimed |
| WO-2004042003-A2 | CELL LYSIS COMPOSITIONS, METHODS OF USE, APPARATUS, AND KIT | PROMEGA CORPORATION (US) | 2004-05-21 | — | — | WO | claimed |
| CN-1141978-C | Method for infecting mouse with pylorospirobacillus | 复旦大学 | 2004-03-17 | — | — | CN | claimed |
| US-6380356-B1 | DIMERS WITH GIVEN LINKING GROUPS; USE AGAINST GRAM-NEGATIVE BACTERIAL INFECTIONS | ADVANCED MEDICINE, INC. | 2002-04-30 | — | — | US | claimed |
| CN-1304729-A | Method for infecting mouse with pylorospirobacillus | UNIV FUDAN (CN) | 2001-07-25 | — | — | CN | claimed |
| EP-0508724-B1 | Radiopharmaceutical bacteriostats | MERCK FROSST CANADA INC (CA) | 1996-08-07 | — | — | EP | claimed |
| US-5306482-A | Benz(alk or eth)orium chloride | MERCK FROSST CANADA, INC. (CA) | 1994-04-26 | — | — | US | claimed |
| WO-1992017184-A2 | BIOACTIVE TOPICAL SILOXANE COMPOSITIONS HAVING ENHANCED PERFORMANCE AND SAFETY | SPECIAL ADVANCED BIOMATERIALS, INC. (US) | 1992-10-15 | — | — | WO | claimed |
| EP-0508724-A1 | Radiopharmaceutical bacteriostats | MERCK FROSST CANADA INC. (CA) | 1992-10-14 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250241979-A1 | NOVEL COMPOUNDS AND THERAPEUTICS USES THEREOF | MAVS, MYD88, CD47 | KDM1A 4216/4885RCOR1 3890/4885LDHB 1565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.